nilvadipine has been researched along with Disease Models, Animal in 11 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 7.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| " The aim of the present study was to examine whether the CCBs nilvadipine and diltiazem reduce ocular inflammation in endotoxin-induced uveitis (EIU)." | 7.76 | Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. ( Ishida, S; Koto, T; Nagai, N; Oike, Y, 2010) |
| "To investigate the effect of nilvadipine, a calcium channel blocker, upon the retina of retinal degeneration slow (rds) mouse, nilvadipine was intraperitoneally injected into heterozygous rds mice for up to 200 days." | 7.74 | Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse. ( Mizukoshi, S; Nakazawa, M; Takeuchi, K, 2008) |
| " In this study, we tested the effects of a synthesized juxtaposition (named SCR1693) composed of an acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB) on the hyperhomocysteinemia (HHcy)-induced AD rat model, and found that SCR1693 remarkably improved the HHcy-induced memory deficits and preserved dendrite morphologies as well as spine density by upregulating synapse-associated proteins PSD95 and synapsin-1." | 3.80 | Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats. ( Chen, R; Hu, J; Liu, R; Liu, X; Tian, Q; Wang, JZ; Wang, P; Wang, Q; Wang, XC; Xia, Y; Zeng, K, 2014) |
| " The aim of the present study was to examine whether the CCBs nilvadipine and diltiazem reduce ocular inflammation in endotoxin-induced uveitis (EIU)." | 3.76 | Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis. ( Ishida, S; Koto, T; Nagai, N; Oike, Y, 2010) |
| "To investigate the effect of nilvadipine, a calcium channel blocker, upon the retina of retinal degeneration slow (rds) mouse, nilvadipine was intraperitoneally injected into heterozygous rds mice for up to 200 days." | 3.74 | Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse. ( Mizukoshi, S; Nakazawa, M; Takeuchi, K, 2008) |
| "Nilvadipine was administered from P7 to P28." | 1.37 | AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency. ( Allocca, M; Auricchio, A; Di Vicino, U; Iodice, C; Manfredi, A, 2011) |
| "The development of Alzheimer's disease (AD) is generally thought to correlate with cerebral accumulation of Abeta." | 1.32 | Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. ( Crawford, F; Crescentini, R; Humphrey, J; Mullan, M; Paris, D; Patel, N; Quadros, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, Y | 1 |
| Liu, R | 1 |
| Chen, R | 1 |
| Tian, Q | 1 |
| Zeng, K | 1 |
| Hu, J | 1 |
| Liu, X | 1 |
| Wang, Q | 1 |
| Wang, P | 1 |
| Wang, XC | 1 |
| Wang, JZ | 1 |
| Ishida, S | 1 |
| Koto, T | 1 |
| Nagai, N | 1 |
| Oike, Y | 1 |
| Sakamoto, K | 1 |
| Mori, A | 1 |
| Nakahara, T | 1 |
| Ishii, K | 2 |
| Allocca, M | 1 |
| Manfredi, A | 1 |
| Iodice, C | 1 |
| Di Vicino, U | 1 |
| Auricchio, A | 1 |
| Mayama, C | 1 |
| Ota, T | 1 |
| Tomidokoro, A | 1 |
| Araie, M | 1 |
| Takano, Y | 2 |
| Ohguro, H | 3 |
| Ohguro, I | 1 |
| Yamazaki, H | 2 |
| Mamiya, K | 1 |
| Ishikawa, F | 1 |
| Nakazawa, M | 3 |
| Paris, D | 1 |
| Quadros, A | 1 |
| Humphrey, J | 1 |
| Patel, N | 1 |
| Crescentini, R | 1 |
| Crawford, F | 1 |
| Mullan, M | 1 |
| Takeuchi, K | 1 |
| Mizukoshi, S | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Seki, T | 1 |
| Adachi, C | 1 |
| Yoshimoto, T | 1 |
| Mishina, N | 1 |
| Imaki, T | 1 |
| Naruse, K | 1 |
| Demura, R | 1 |
| Demura, H | 1 |
| Maeda, T | 1 |
| Maruyama, I | 1 |
| Metoki, T | 1 |
| Sawada, H | 1 |
| Dezawa, M | 1 |
2 reviews available for nilvadipine and Disease Models, Animal
| Article | Year |
|---|---|
[Cause of retinitis pigmentosa and new therapeutics under development].
Topics: Animals; c-Mer Tyrosine Kinase; Carrier Proteins; cis-trans-Isomerases; Cyclic Nucleotide Phosphodie | 2011 |
[New drug therapy for retinal degeneration].
Topics: Animals; Calcium Channel Blockers; Dark Adaptation; Disease Models, Animal; Humans; Mice; Mutation; | 2008 |
9 other studies available for nilvadipine and Disease Models, Animal
| Article | Year |
|---|---|
Novel multipotent AChEI-CCB attenuates hyperhomocysteinemia-induced memory deficits and Neuropathologies in rats.
Topics: Animals; Brain Diseases; Calcium Channel Blockers; Cholinesterase Inhibitors; Disease Models, Animal | 2014 |
Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular inflammation in endotoxin-induced uveitis.
Topics: Animals; Blood-Aqueous Barrier; Calcium Channel Blockers; Cell Adhesion; Chemokine CCL2; Diltiazem; | 2010 |
AAV-mediated gene replacement, either alone or in combination with physical and pharmacological agents, results in partial and transient protection from photoreceptor degeneration associated with betaPDE deficiency.
Topics: Animals; Calcium Channel Blockers; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Cycli | 2011 |
Changes in optic nerve head circulation in response to vasoactive agents: intereye comparison in monkeys with experimental unilateral glaucoma.
Topics: Animals; Arginine; Blood Circulation; Blood Flow Velocity; Calcium Channel Blockers; Disease Models, | 2012 |
Low expression of rhodopsin kinase in pineal gland in Royal College of Surgeons rat.
Topics: Animals; Arrestin; Blotting, Western; Calcium Channel Blockers; Calcium-Binding Proteins; Disease Mo | 2003 |
Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aorta; Calcium Channel B | 2004 |
Systemic administration of nilvadipine delays photoreceptor degeneration of heterozygous retinal degeneration slow (rds) mouse.
Topics: Animals; Blotting, Western; Calcium Channel Blockers; Disease Models, Animal; Drug Evaluation, Precl | 2008 |
Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Blotting, Southern; Brain; Calcium Channel Blockers; Cardiovascular | 1999 |
Preservation of retinal morphology and functions in royal college surgeons rat by nilvadipine, a Ca(2+) antagonist.
Topics: Animals; Blotting, Western; Calcium Channel Blockers; Caspase 1; Caspase 2; Caspases; Crystallins; D | 2002 |